To the Editor: The article by Philip Sambrook et al on the impact of adverse news media on prescriptions for osteoporosis1 contains a number of serious errors and ignores more recent data.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Sambrook PN, Chen JS, Simpson JM, March LM. Impact of adverse news media on prescriptions for osteoporosis: effect on fractures and mortality. Med J Aust 2010; 193: 154-156. <MJA full text>
- 2. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22: 1479-1491.
- 3. Lo JC, O’Ryan FS, Gordon NP, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010; 68: 243-253.
- 4. Mavrokkoki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65: 415-423.
- 5. Stone KL, Seeley DG, Lui LY, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 2003; 18: 1947-1954.
- 6. Boles v Merck & Co. Case no. 06-CV-9455. In re Fosamax products liability litigation, MDL 1789, US District Court, Southern District of New York (Manhattan).
Online responses are no longer available. Please refer to our instructions for authors page for more information.
Alastair Goss has been a consultant to Merck and Novartis on ONJ, and has provided expert testimony for the plaintiffs in the US class action against Merck with respect to alendronate.